ConductScience.org, home

Paper6985698

Cancer of the breast: the past decade (first of two parts).

Henderson IC and 1 other. N Engl J Med, 1980. Cited by 448 papers, by iCite.

Cite this record

ConductScience Library. Cancer of the breast: the past decade (first of two parts). Papers, record 6985698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6985698

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cancer of the breast: the past decade (first of two parts).
PubMed
Journal
N Engl J Med
PubMed
Year
1980
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
448
iCite
Relative citation ratio, by iCite
17.5
iCite
Revised in PubMed
2004-11-17
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Henderson ICI C
2Canellos GPG P

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Adrenalectomy
Castration
Female
Follow-Up Studies
Hormones
Humans
Hypophysectomy
Mammography
Mastectomy
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Random Allocation
Time Factors

Source PubMed

Download CSV of topics

Cited by58

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 448 citations.

PMIDTitleJournalYearIn PapersSource
36795198Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer.Drug Deliv Transl Res2023https://conductscience.org/library/papers/36795198PubMed
34524841NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers.Sci Adv2021https://conductscience.org/library/papers/34524841PubMed
34124226A Novel Canine Mammary Cancer Cell Line: Preliminary Identification and Utilization for Drug Screening Studies.Front Vet Sci2021https://conductscience.org/library/papers/34124226PubMed
32707666Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer.Cancers (Basel)2020https://conductscience.org/library/papers/32707666PubMed
3248567990 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future.J Mol Endocrinol2020https://conductscience.org/library/papers/32485679PubMed
27801993Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.Cancer Sci2017https://conductscience.org/library/papers/27801993PubMed
26069501Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics.Cancer Nanotechnol2013https://conductscience.org/library/papers/26069501PubMed
22866165Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells.J Cancer2012https://conductscience.org/library/papers/22866165PubMed
22675673Radiation, inflammation, and immune responses in cancer.Front Oncol2012https://conductscience.org/library/papers/22675673PubMed
21290426In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugs.Arch Pharm (Weinheim)2011https://conductscience.org/library/papers/21290426PubMed
20556210Synthesis and antiproliferative activity of coumarin-estrogen conjugates against breast cancer cell lines.Lett Drug Des Discov2009https://conductscience.org/library/papers/20556210PubMed
18991629A review of coumarin derivatives in pharmacotherapy of breast cancer.Curr Med Chem2008https://conductscience.org/library/papers/18991629PubMed
18748967The halsted mastectomy.West J Med1981https://conductscience.org/library/papers/18748967PubMed
17429562A new hormonal therapy for estrogen receptor-negative breast cancer.World J Surg2007https://conductscience.org/library/papers/17429562PubMed
12114657From Endocrinology to Intracrinology.Endocr Pathol1998https://conductscience.org/library/papers/12114657PubMed
11091546Growth of Breast Cancer and Limited Surgery.Breast Cancer1996https://conductscience.org/library/papers/11091546PubMed
10947336New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits.Pharmacoeconomics2000https://conductscience.org/library/papers/10947336PubMed
9712568Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.Ann Surg1998https://conductscience.org/library/papers/9712568PubMed
8174206Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8174206PubMed
8123487Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma.Br J Cancer1994https://conductscience.org/library/papers/8123487PubMed

See all 58 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6985698

GET https://conductscience.org/api/papers/v1/6985698/cited_by?page=2